Mindray Medical has made another acquisition to add more products to its medical device portfolio. This time, Mindray paid $35.5 million for a controlling stake in Wuhan Dragonbio Surgical Implant Co., a company that makes trauma, spine, joint and other orthopedic products. Until now, Mindray’s traditional areas of business have been patient monitoring, in-vitro diagnostics, and medical imaging. More details.... Stock Symbol: (NYSE: MR) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});